Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 1-Year High – Still a Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $65.30 and last traded at $64.1150, with a volume of 1200 shares. The stock had previously closed at $64.53.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on KNSA shares. Citigroup lifted their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, June 29th. Wells Fargo & Company upped their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Monday, May 4th. Finally, Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $62.71.

Kiniksa Pharmaceuticals International Stock Up 7.2%

The company’s fifty day moving average is $55.05 and its two-hundred day moving average is $48.11. The stock has a market cap of $5.18 billion, a price-to-earnings ratio of 74.77 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.11 EPS. Sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 13,099 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $628,554.60. The trade was a 51.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the transaction, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 636,755 shares of company stock worth $33,222,062 over the last three months. Company insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Qube Research & Technologies Ltd increased its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after purchasing an additional 526,567 shares during the period. Bank of America Corp DE boosted its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares during the period. Cubist Systematic Strategies LLC grew its stake in Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after buying an additional 447,536 shares during the last quarter. Finally, Spruce Street Capital LP purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $17,943,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.